Core Viewpoint - The regulatory authority has imposed penalties on Jiaying Pharmaceutical and its responsible individuals for violations related to information disclosure, specifically concerning the failure to timely disclose a 220 million yuan related party fund borrowing [1][2]. Summary by Sections Regulatory Actions - Jiaying Pharmaceutical and its key personnel received a total fine of 4.9 million yuan due to the failure to disclose 220 million yuan in related party fund borrowing [1][2]. - The Guangdong Securities Regulatory Bureau issued a warning and fines of 1.5 million yuan to Jiaying Pharmaceutical, 1.6 million yuan to Chairman Li Neng, 1 million yuan to General Manager You Yongping, and 800,000 yuan to former CFO Shi Junping [3]. Related Party Transactions - The related party transactions involved Jiaying Pharmaceutical's subsidiary, Jiaying Pharmaceutical (Hunan) Co., Ltd., providing short-term fund borrowing to Hunan Yaoyang, a company controlled by Li Neng, with amounts ranging from 40,000 to 59.99 million yuan [2][3]. - The total amount borrowed in 2024 was 170 million yuan, with an additional 50 million yuan in January 2025, representing 28.83% of Jiaying Pharmaceutical's latest audited net assets [2]. Management Accountability - Li Neng, as the chairman, is directly responsible for the information disclosure violations, while You Yongping and Shi Junping also hold direct responsibility due to their managerial roles [3]. - The violations occurred shortly after Li Neng's appointment as chairman, indicating potential misconduct in managing company funds [4]. Financial Context of Related Companies - Hunan Yaoyang, controlled by Li Neng, has faced significant financial challenges, with 2024 revenues of 1.165 billion yuan and a net profit of 49.93 million yuan, which are substantially lower compared to competitors [5]. - The company has struggled to secure financing through public offerings, leading to reliance on brand cooperation and franchise models, resulting in only about 4,000 stores compared to competitors with over 10,000 [5].

Core Viewpoint - Jia Ying Pharmaceutical has been fined a total of 4.9 million yuan due to violations of information disclosure laws, which has raised concerns about its governance and financial practices [3][5][6]. Group 1: Regulatory Actions - Jia Ying Pharmaceutical and related responsible persons received a total fine of 4.9 million yuan from the China Securities Regulatory Commission (CSRC) [3]. - The company’s subsidiary, Hunan Jia Ying, provided a total of 220 million yuan in short-term loans to a company controlled by its actual controller, Li Neng, without proper disclosure [3][6]. - The fines include 150,000 yuan for the company, 1.6 million yuan for Li Neng, 1 million yuan for the general manager, and 800,000 yuan for the former financial director [3]. Group 2: Financial Performance - Jia Ying Pharmaceutical has experienced a decline in revenue and net profit over the past two years, with 2024 revenue dropping to 376 million yuan, a decrease of 29.46% year-on-year, and net profit falling to 20.61 million yuan, down 39.94% [14]. - The company reported a significant drop in operating cash flow, turning negative at -11.83 million yuan, a year-on-year decline of 193.73% [16]. - Accounts receivable surged by 40.48% to 132 million yuan, indicating potential liquidity issues [17]. Group 3: Management Changes - The company has seen frequent changes in its executive team, with the resignation of key personnel including the secretary and financial director earlier this year [12]. - Li Neng took over as chairman of Jia Ying Pharmaceutical in August 2024, shortly before the financial misconduct occurred [7][8]. Group 4: Market Reaction - Following the announcement of the regulatory penalties, Jia Ying Pharmaceutical's stock rose by 3.12%, with a total market capitalization of 3.527 billion yuan as of August 1 [1]. - Since June 20, the stock has experienced an upward trend, with a cumulative increase of over 16% [1].

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to potential administrative penalties [1][2]. Summary by Sections Investigation and Allegations - The CSRC issued a notice of investigation due to Jiaying Pharmaceutical's alleged violations of information disclosure laws, specifically related to transactions with its related party, Hunan Yaojuneng Pharmaceutical Co., Ltd. [1][2]. - Between October 2024 and January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to Hunan Yaojuneng, totaling CNY 219.99 million, which accounted for 28.83% of Jiaying Pharmaceutical's latest audited net assets [2]. Legal Basis and Responsibilities - The actions of Jiaying Pharmaceutical are suspected to violate multiple articles of the Securities Law, including provisions regarding the disclosure of related party transactions [3]. - Key executives, including the chairman and general manager, are identified as directly responsible for the violations, with specific penalties proposed for each individual involved [3][4]. Proposed Penalties - The CSRC plans to impose a warning and a fine of CNY 1.5 million on Jiaying Pharmaceutical, along with individual fines for the chairman (CNY 1.6 million), the general manager (CNY 1 million), and the former financial director (CNY 800,000) [4]. Impact on Operations - Despite the ongoing investigation, Jiaying Pharmaceutical's operations remain normal, and the company asserts that the situation will not significantly impact its business activities [4].

因信息披露违法违规被立案后，监管对嘉应制药（002198）及相关责任人的处罚落地。此前公司在5月 28日晚曾公告，因公司涉嫌信息披露违法违规，中国证监会决定对公司立案。（详见本报5月29日报道 本报报道后，002198被立案调查了！） 8月3日晚间，嘉应制药公告，8月1日，公司及相关责任人李能（现任董事长）、游永平（现任董事、总 经理）、史俊平（时任财务总监）收到中国证监会广东监管局下发的《行政处罚事先告知书》（以下简 称《行政处罚书》），因2.2亿元关联资金拆借未及时披露，嘉应制药及相关责任人合计领490万元罚 单。 嘉应制药及相关责任人领490万元罚单 《行政处罚书》显示，嘉应制药董事长李能是湖南药聚能医药有限公司（以下简称"药聚能"）的实际控 制人，药聚能构成嘉应制药的关联方。2024年10月至2025年1月期间，因药聚能存在短期资金需求，嘉 应制药的子公司嘉应制药（湖南）有限公司（以下简称"湖南嘉应"）以月初转出、月末转回的方式，向 药聚能提供短期资金拆借，单笔发生额在4万元至5999万元之间。其中，2024年度合计转出1.7亿元； 2025年1月转出5000万元，并均于当月转回，累计涉及金额为2.2 ...

Core Viewpoint - Jia Ying Pharmaceutical (002198) received an administrative penalty notice due to the chairman's misuse of company funds through an affiliated company [1][5] Group 1: Administrative Penalty - The company and responsible individuals, including Chairman Li Neng, General Manager You Yongping, and former CFO Shi Junping, received a notice from the Guangdong Regulatory Bureau of the China Securities Regulatory Commission (CSRC) on August 1 [1][6] - The CSRC decided to investigate the company for suspected violations of information disclosure laws, leading to the administrative penalty [1][5] Group 2: Fund Misappropriation Details - Li Neng, as the actual controller of Hunan Yao Juneng Pharmaceutical Co., Ltd. (an affiliate), facilitated the transfer of funds from Jia Ying Pharmaceutical to this company, which constituted a non-operational fund transfer [5][6] - From October 2024 to January 2025, Jia Ying Pharmaceutical's subsidiary transferred a total of 21.999 million yuan to the affiliate, representing 28.83% of the company's latest audited net assets [5][6] Group 3: Penalties Imposed - The proposed penalties include a warning and a fine of 1.5 million yuan for Jia Ying Pharmaceutical, a warning and a fine of 1.6 million yuan for Li Neng, a warning and a fine of 1 million yuan for You Yongping, and a warning and a fine of 800,000 yuan for Shi Junping [6][7] Group 4: Background of Li Neng - Li Neng became the chairman of Jia Ying Pharmaceutical in August 2024, just two months before the fund misappropriation occurred [8] - He is also the actual controller of the chain pharmacy Yang Tian He, which has over 4,000 stores nationwide and ranks among the top 20 in China's pharmaceutical retail industry [8] Group 5: Company Overview - Jia Ying Pharmaceutical, established in 2003 and listed in 2007, is a Chinese traditional medicine manufacturer with a portfolio of 70 products [9] - The company has maintained modest financial performance, with total revenues around several hundred million yuan and net profits in the tens of millions [9][10]

证券代码：002198 证券简称：嘉应制药 公告编号：2025-042 广东嘉应制药股份有限公司 关于公司及相关责任人收到《行政处罚事先告知书》的公告 本公司及董事会保证本公告内容的真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日收 到中国证券监督管理委员会（以下简称"中国证监会"）下发的《立案告知书》 （编号：证监立案字 0062025010 号）。因公司涉嫌信息披露违法违规，根据《中 华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会 决定对公司立案。具体内容详见公司于 2025 年 5 月 29 日披露在《证券时报》《中 国证券报》《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）的《关于收 到中国证券监督管理委员会立案告知书的公告》（公告编号：2025-033）。 2025 年 8 月 1 日，公司及相关责任人李能先生（现任董事长）、游永平先 生（现任董事、总经理）、史俊平先生（时任财务总监）收到中国证监会广东监 管局下发的《行政处罚事先告知书》（广东证监处罚字[2 ...

| 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 688766 | 普冉股 | 7.79 | 5.03 | 64.60 | 68.94 | 6.72 | | | 份 | | | | | | | 300679 | 电连技 术 | 8.00 | 4.36 | 47.49 | 50.50 | 6.34 | | 300045 | 华力创 | 6.25 | 8.30 | 20.24 | 21.25 | 4.99 | | | 通 | | | | | | | 600238 | *ST椰岛 | 4.93 | 3.25 | 7.03 | 7.23 | 2.85 | | 300761 | 立华股 | 2.54 | 0.92 | 19.35 | 19.79 | 2.29 | | | 份 | | | | | | | 000703 | 恒逸石 化 | 2.13 | 0.30 | 6.09 | 6.22 | 2.09 | | ...

近日，公司收到戴儒荣、李俊国先生的通知，其已按照相关规定参加了深圳 证券交易所举办的上市公司独立董事培训，并取得了由深圳证券交易所创业企业 培训中心颁发的《上市公司独立董事培训证明》。 特此公告。 广东嘉应制药股份有限公司董事会 关于独立董事取得培训证明的公告 证券代码：002198 证券简称：嘉应制药 公告编号：2025-041 本公司及董事会保证本公告内容的真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2025 年 3 月 27 日召开 2025 年第一次临时股东大会，审议通过了《关于补选第七届董事会独立董事的 议案》，选举戴儒荣、李俊国先生为第七届董事会独立董事，任期自股东大会审 议通过之日起至第七届董事会任期届满日止。 广东嘉应制药股份有限公司 截至公司 2025 年第一次临时股东大会通知发出之日，戴儒荣、李俊国先生 尚未取得上市公司独立董事资格证书。根据深圳证券交易所的相关规定，戴儒荣、 李俊国先生已书面承诺参加最近一次独立董事培训并取得深圳证券交易所认可 的独立董事资格证书。 2025 年 7 月 29 日 ...

Group 1 - On July 9, 2025, the company received a financing buy-in of 1.8009 million yuan, accounting for 9.49% of the total buy-in amount for the day, with a current financing balance of 237 million yuan, representing 7.23% of the circulating market value, which is below the historical 50% percentile level [2] - On May 28, 2025, the company announced that it received a notice of investigation from the China Securities Regulatory Commission (CSRC) due to suspected violations of information disclosure laws, leading to a formal investigation [2] - Investors who purchased shares before May 28, 2025, and held them until the market close on that date may be eligible for compensation due to the company's alleged information disclosure violations [2] Group 2 - On December 12, 2024, the company’s board approved a share repurchase plan, intending to buy back between 7 million and 13.5 million shares at a maximum price of 9.8 yuan per share, with a total repurchase amount not exceeding 132.3 million yuan [3] - The company initiated its first share repurchase on January 3, 2025, and as of March 31, 2025, it had repurchased 7.1871 million shares, accounting for 1.42% of the total share capital, with a total transaction amount of 49.4693 million yuan [3][4] - The funds for the share repurchase are sourced from the company's own funds, and the repurchase price did not exceed the proposed maximum price of 9.8 yuan per share [4] Group 3 - The company holds 82 trademark registrations and 11 patents, along with 268 administrative licenses, indicating a robust intellectual property portfolio [4]

证券代码：002198 证券简称：嘉应制药 公告编号：2025-040 2025年1月3日，公司首次实施了股份回购。根据《深圳证券交易所上市公司 自律监管指引第9号——回购股份》等相关规定，公司在回购期间应当在每个月 的前三个交易日内披露截至上月末的回购进展情况。现将公司截至上月末的回购 进展情况公告如下： 二、股份回购进展情况 截至2025年6月30日，公司通过股票回购专用证券账户以集中竞价方式已累 计回购公司股份9,096,100股，占公司目前总股本的1.7923%，回购的最高成交价 格为7.04元/股，最低成交价格为5.96元/股，成交总金额为61,294,115.00元（不含 交易费用）。 广东嘉应制药股份有限公司 关于股份回购进展情况的公告 本公司及董事会保证本公告内容的真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 一、回购方案的主要内容 广东嘉应制药股份有限公司（以下简称"公司"）于2024年12月12日召开的 第七届董事会第四次临时会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金以集中竞价方式回购部分公司已发行的人民币普通股（A 股）股票，回购的股份将用于实 ...